The global healthcare landscape is increasingly complex, driven by rapid technological advances, shifting patient demographics, and rising prevalence of chronic diseases such as diabetes, cardiovascular disorders, and respiratory conditions. For pharma companies, medtech manufacturers, payers, and investors, market intelligence on chronic diseases is no longer optional—it is a strategic imperative. High-quality market research provides insights into disease epidemiology, treatment trends, patient outcomes, and competitive dynamics, enabling informed decisions across R&D, commercialization, portfolio strategy, and M&A.
The following is a curated list of the top 10 market research providers for chronic diseases analysis, evaluated for data depth, analytic capability, therapeutic expertise, client services, and strategic impact.
IQVIA has established itself as a dominant force in healthcare data and analytics. Its Connected Intelligence platform integrates claims, electronic medical records (EMRs), prescription and provider data, clinical trial execution, and commercial performance. For chronic diseases, IQVIA offers detailed epidemiology insights, patient journey mapping, treatment patterns, and real-world evidence (RWE) analytics.
Executives rely on IQVIA for its scalable platforms, robust datasets, and predictive models to support forecasting, launch planning, and portfolio prioritization. Its reports and data-driven insights are particularly valuable for global strategy teams seeking to optimize chronic disease programs and assess therapeutic opportunities across multiple geographies.
Clarivate, including its Decision Resources Group (DRG) capabilities, provides comprehensive life sciences intelligence, blending clinical, commercial, and payer datasets. Its chronic disease coverage spans therapeutic trends, competitive landscaping, market sizing, and payer reimbursement analysis.
By consolidating proprietary databases, expert networks, and workflow tools, Clarivate helps executives make high-stakes decisions in portfolio management, licensing, and asset valuation. For organizations targeting complex chronic disease markets, Clarivate’s combination of analytical rigor and domain expertise ensures actionable, reliable insights.
Evaluate is a specialist in pharmaceutical forecasting and commercial intelligence. Its Evaluate Pharma datasets, complemented by tools like Biomedtracker and Pharmapremia, offer forward-looking sales forecasts, probability assessments, and deal-making insights for chronic disease therapeutics.
Investors, corporate strategy teams, and pharma executives utilize Evaluate to stress-test financial scenarios, assess pipeline risk, and support M&A diligence. Its chronic disease-focused reports provide a clear view of market potential, competitive threats, and revenue projections, making it indispensable for decision-making in complex therapeutic areas.
4. DelveInsight – Deep Therapeutic Focus and Tailored Consulting
DelveInsight stands out for its therapeutic expertise in chronic diseases, including oncology, cardiovascular, metabolic, and respiratory conditions. The firm combines market research with consulting services to deliver tailored analyses such as market access studies, pipeline landscapes, clinical development insights, and competitive intelligence.
Mid-sized biotechs, global pharma teams, and investors turn to DelveInsight for actionable, therapy-specific intelligence that goes beyond generic datasets. Its combination of specialist analysts and consultative services makes it a practical choice when detailed, granular insights are needed for R&D strategy, launch planning, or commercial execution in chronic disease markets.
Informa’s Pharma Intelligence division provides extensive clinical trial intelligence, regulatory tracking, and commercial analytics. For chronic diseases, its platforms track pipeline progress, investigator networks, trial performance, and regulatory developments across multiple geographies.
Pharma companies rely on Informa to benchmark clinical programs, identify strategic partners, and evaluate competitive dynamics. Its comprehensive coverage ensures that executives remain informed of the latest clinical trends and regulatory changes impacting chronic disease therapies.
Frost & Sullivan blends market research with strategic consulting, offering growth-oriented insights and scenario planning for chronic disease markets. Its reports cover emerging treatment modalities, digital health integration, and market entry opportunities.
For medtech manufacturers, digital health innovators, and healthcare investors, Frost’s value lies in translating complex data into actionable growth strategies and go-to-market frameworks, helping organizations capitalize on new opportunities and white-space markets in chronic disease care.
McKinsey’s life sciences practice pairs market intelligence with operational and strategic execution, providing a bridge between analytics and enterprise transformation. Its chronic disease coverage includes R&D optimization, launch sequencing, pricing strategy, and digital/AI adoption.
While not a traditional data vendor, McKinsey helps healthcare organizations operationalize insights, turning intelligence into actionable business decisions and large-scale transformation programs, particularly relevant for global pharmaceutical and medtech teams navigating complex chronic disease markets.
GlobalData Healthcare offers end-to-end data and analytics on therapeutic areas, including chronic diseases. Its services cover epidemiology, treatment landscapes, competitive intelligence, and market sizing.
Executives rely on GlobalData to identify unmet needs, evaluate pipeline potential, and assess strategic risks. Its combination of proprietary datasets, AI-driven insights, and expert commentary ensures clarity in decision-making, especially for international chronic disease programs.
MRFR provides detailed market research reports across chronic disease segments, including diabetes, cardiovascular disorders, and respiratory conditions. Its analyses focus on market trends, growth drivers, competitive landscapes, and investment opportunities.
Pharma companies and investors utilize MRFR to benchmark market performance, evaluate segment potential, and inform strategic planning. Its reports offer actionable intelligence for both established and emerging chronic disease markets, supporting tactical and long-term decisions.
Global Market Insights delivers market research and forecasting solutions for healthcare and chronic disease markets. Its services include market sizing, trend analysis, and competitive benchmarking.
Healthcare executives and investors rely on its reports to guide investment decisions, prioritize therapeutic areas, and anticipate market shifts. The firm’s insights help organizations maintain strategic agility in complex and evolving chronic disease landscapes.
How to Choose the Right Provider for Chronic Disease Analysis
Selecting a market research provider depends on organizational needs, use cases, and strategic priorities. Consider the following:
Data Depth and Quality: Ensure the provider offers detailed, patient-level or real-world data relevant to the specific chronic disease.
Analytic Capabilities: AI-driven forecasting, predictive modelling, and epidemiological analysis are critical for accurate decision-making.
Therapeutic Expertise: Providers with deep domain knowledge can translate complex data into actionable insights.
Consulting and Advisory Services: For strategic planning, some providers also offer bespoke consulting and scenario analysis.
Global Coverage: Chronic disease markets are often global; ensure the provider has multi-country or region-specific datasets.
Combining a large-scale data provider (like IQVIA or Clarivate) with a specialist firm (such as DelveInsight or Frost) often yields the best return on investment for chronic disease intelligence.
Future Trends in Chronic Disease Market Research
The chronic disease market is evolving rapidly due to AI, real-world evidence, digital health, and patient-level analytics. Providers increasingly offer integrated platforms combining clinical, commercial, and regulatory intelligence. Transparency in data sources, methodology, and modeling assumptions is becoming a non-negotiable requirement, particularly when insights inform investment decisions, regulatory submissions, or global launches.
Organizations leveraging these advanced analytics and expert interpretation will gain a competitive edge, accelerate product development, and optimize market access in the fast-moving chronic disease space.
Conclusion
Accurate, timely, and actionable market intelligence is critical for navigating the complexities of chronic disease markets. The top 10 providers listed here—including IQVIA, Clarivate, Evaluate, and DelveInsight—offer a blend of data depth, analytic sophistication, therapeutic expertise, and strategic insight to support informed decision-making. By selecting the right combination of large-scale integrated platforms and specialized consultancies, healthcare executives, pharma companies, and investors can maximize the value of chronic disease market research, driving growth, innovation, and better patient outcomes.